Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NT5E | P21589 | 15/20 | 1.00 |
| ▸ | PLCG1 | P19174 | 1/20 | 0.75 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.75 |
| ▸ | P2RY1 | P47900 | 4/20 | 0.75 |
| ▸ | P2RY11 | Q96G91 | 2/20 | 0.75 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30563042 | 0.92 | NT5E (1.00) | NT5E | |
| SCHEMBL19100957 | 0.92 | NT5E (1.00) | NT5E | |
| SCHEMBL25363268 | 0.91 | NT5E (0.86) | NT5E | |
| SCHEMBL26030648 | 0.91 | NT5E (0.86) | NT5E | |
| SCHEMBL8423402 | 0.91 | P2RY1 (0.83) | NT5EP2RY1P2RY11 | |
| SCHEMBL8423419 | 0.91 | P2RY1 (0.83) | NT5EP2RY1P2RY11 | |
| SCHEMBL10120960 | 0.91 | P2RY1 (0.83) | NT5EP2RY1P2RY11 | |
| SCHEMBL19366734 | 0.89 | NT5E (1.00) | NT5EPLCG1ENPP1P2RY1 | |
| SCHEMBL19100539 | 0.89 | NT5E (1.00) | NT5EPLCG1ENPP1P2RY1 | |
| SCHEMBL26031925 | 0.89 | NT5E (0.84) | NT5EPLCG1ENPP1P2RY1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11667662-B2 | Modulators of 5′-nucleotidase, ecto and the use thereof | ARCUS BIOSCIENCES, INC. (US) | 2023-06-06 | — | — | US | disclosed |
| US-20190309010-A1 | MODULATORS OF 5'-NUCLEOTIDASE, ECTO AND THE USE THEREOF | ARCUS BIOSCIENCES, INC. | 2019-10-10 | — | — | US | disclosed |
| US-10239912-B2 | Modulators of 5′-nucleotidase, ecto and the use thereof | ARCUS BIOSCIENCES, INC. (US) | 2019-03-26 | — | — | US | disclosed |
| US-20170267710-A1 | MODULATORS OF 5'-NUCLEOTIDASE, ECTO AND THE USE THEREOF | ARCUS BIOSCIENCES, INC. | 2017-09-21 | — | — | US | disclosed |
| EP-0508687-B1 | ATP analogues | FISONS PLC (GB) | 1995-09-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170267710-A1 | MODULATORS OF 5'-NUCLEOTIDASE, ECTO AND THE USE THEREOF | ENTPD5, NT5C2, NT5E | NT5E 3/4885PLCG1 309/4885ENPP1 5/4885 |
| US-20190309010-A1 | MODULATORS OF 5'-NUCLEOTIDASE, ECTO AND THE USE THEREOF | ENTPD5, NT5C2, NT5E | NT5E 3/4885PLCG1 309/4885ENPP1 5/4885 |
| US-11667662-B2 | Modulators of 5′-nucleotidase, ecto and the use thereof | ENTPD5, NT5C2, NT5E | NT5E 3/4885PLCG1 309/4885ENPP1 5/4885 |
| US-10239912-B2 | Modulators of 5′-nucleotidase, ecto and the use thereof | ENTPD5, NT5C2, NT5E | NT5E 3/4885PLCG1 309/4885ENPP1 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.